MDM2-p53 Antagonist BI 907828 Demonstrated Promising Activity in Patients with Advanced BTC

March 2023, Vol 4, No 1

A clinical need to enhance first-line treatment outcomes in patients with advanced biliary tract cancer (BTC) is clear, and with a lack of effective second-line therapies, the development of effective targeted treatments is necessary. It has been suggested that blocking the MDM2-p53 interaction has the potential for antitumor activity, as MDM2 is a negative regulator of p53, and MDM2 amplification has been seen as a negative prognostic marker in BTC in preliminary data.

BI 907828 is an MDM2-p53 antagonist that has shown antitumor activity in preclinical studies in a range of tumor types. Currently, BI 907828 is being studied in 2 phase 1a/1b dose-escalation/expansion trials in patients with advanced solid tumors as monotherapy and in combination with anti–PD-1 monoclonal antibody ezabenlimab in a variety of TP53 wild-type cancers. Dr Noboru Yamamoto presented efficacy and safety data for patients with advanced BTC in these trials.

Of the first 10 patients with BTC enrolled in the trials, 6 patients were enrolled in the monotherapy trial and received escalating doses of BI 907828 every 3 weeks (arm A) or days 1, 8, and every 4 weeks (arm B), and 4 patients were enrolled in the combination trial and received escalating doses of BI 907828 plus 240 mg of ezabenlimab every 3 weeks (doublet). In the monotherapy trial, 3 patients had ampullary carcinoma (all received BI 907828 45 mg every 3 weeks), and 3 had cholangiocarcinoma (CCA; 2 patients received BI 907828 45 mg every 3 weeks and 1 patient with intrahepatic CCA [iCCA] received 80 mg every 3 weeks). In the combination trial, 3 patients with iCCA received 30 mg/45 mg BI 907828 doublet or 45 mg triplet (doublet plus the anti–LAG-3 antibody BI 754111), and 1 patient with gallbladder carcinoma (GBC) received BI 907828 45 mg doublet.


The novel MDM2-p53 antagonist BI 907828 demonstrated a manageable safety profile with encouraging efficacy in patients with BTC.

As of December 2022, 2 patients in the monotherapy trial and 3 patients in the combination trial achieved a partial response. In addition, 2 patients in the monotherapy trial and 1 patient in the combination trial achieved stable disease. In the monotherapy trial, 1 responding patient who had iCCA saw 73% tumor shrinkage and a progression-free survival (PFS) event at 404 days. In the combination trial, tumor shrinkage in 1 patient with iCCA was 49% with a PFS event at 230 days, whereas another patient with GBC saw 50% tumor shrinkage with a PFS event at day 241.

In the safety analysis, 71 patients had received BI 907828 every 3 weeks as monotherapy as of April 2022. Of these, 59.2% experienced grade ≥3 treatment-related adverse events (TRAEs), the most common being neutropenia (25.4%), thrombocytopenia (23.9%), decreased white blood cell (WBC) count (11.3%), and anemia (11.3%). A total of 22.5% of patients experienced TRAEs leading to dose reductions, and 7% experienced TRAEs leading to treatment discontinuation. Hematologic adverse events were managed with appropriate treatment or dose modification/interruption. In total, 31 patients had received BI 907828 in combination as of April 2022. Of these, 67.7% experienced a grade 3 or 4 TRAE, and the most common were thrombocytopenia (25.8%), anemia (22.6%), decreased WBC (16.1%) and lymphocyte counts (16.1%), and neutropenia (12.9%). A total of 19.4% of patients required dose reductions due to TRAEs, and there were no discontinuations due to TRAEs. The safety profile in patients with BTC was similar to the overall population.

Overall, the novel MDM2-p53 antagonist BI 907828 demonstrated a manageable safety profile with encouraging efficacy in patients with BTC. A phase 2a/2b trial in patients with BTC is currently recruiting.

Source: Yamamoto N, Tolcher A, Hafez N, et al. Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: data from two phase Ia/Ib dose-escalation/expansion trials. Poster presented at: ASCO Gastrointestinal Cancers Symposium, January 19-21, 2023; San Francisco, CA. Abstract 543.

Related Items

Characterization of Long-Term Survivors in TOPAZ-1
March 2023, Vol 4, No 1
Researchers examined the characteristics, outcomes, and genomic profiles of patients with advanced biliary tract cancer who were treated with durvalumab plus gemcitabine/cisplatin and experienced long-term survival.
Treatment and Survival Outcomes with Systemic Therapy for Patients with BTC with IDH1 Mutations: A Retrospective Study
March 2023, Vol 4, No 1
Long-term outcomes were evaluated in patients with IDH1-mutated biliary tract cancer who were treated with systemic therapy.
Phase 2 Study of CTX-009 plus Paclitaxel in Patients with Advanced BTC
March 2023, Vol 4, No 1
CTX-009 plus paclitaxel showed promising efficacy as second- or third-line treatment in patients with advanced biliary tract cancer.
Gunagratinib in Patients with Previously Treated Advanced CCA Harboring FGFR2 Fusions or Rearrangements
March 2023, Vol 4, No 1
Gunagratinib showed promising efficacy as a second-generation FGFR inhibitor and demonstrated potential to treat multiple FGFR pathway abnormalities.
Results from SWOG 1815: GemCis and Nab-Paclitaxel versus GemCis in Advanced BTC
March 2023, Vol 4, No 1
The SWOG 1815 trial found that treatment with gemcitabine/cisplatin and paclitaxel (GAP) did not result in a significant improvement in survival compared with gemcitabine and cisplatin in patients with advanced biliary tract cancer, though GAP may be beneficial in patients with locally advanced disease and GBC.
JCOG1202 Subgroup Analysis: Risk Factors for Early Relapse in Patients Undergoing Curative Resection
March 2023, Vol 4, No 1
A study of patients with resected biliary tract cancer (BTC) found that postoperative CA 19-9 level, tumor differentiation, lymph node metastases, and residual tumor significantly impact early relapse in patients with curatively resected BTC. Similar risk factors were also found in patients receiving adjuvant S-1.
Impact of Gene Expression in 5-FU Metabolic Pathways on Outcomes in Patients Enrolled in JCOG1202
March 2023, Vol 4, No 1
Results from a study evaluating the impact of 5-FU metabolic pathway enzyme expression on outcomes of patients with curatively resected biliary tract cancer showed that relapse-free survival was improved in patients with certain enzymes who received adjuvant S-1.
Atezolizumab with or without Bevacizumab in Combination with GemCis in Advanced BTC: Results from IMbrave 151
March 2023, Vol 4, No 1
Researchers assessed whether VEGF blockade plus chemotherapy with gemcitabine/cisplatin can enhance responses to PD-L1 inhibition by promoting an immune-permissive tumor microenvironment in patients with advanced biliary tract cancer.
Nab-Paclitaxel plus Sintilimab as Second-Line Treatment for Advanced BTC
March 2023, Vol 4, No 1
The safety and efficacy of second-line nab-paclitaxel combined with the anti-PD-1 antibody sintilimab was studied in patients with advanced biliary tract cancer.
ICIs as Salvage Therapy for BTCs with KRAS Mutation
March 2023, Vol 4, No 1
Results are presented from a retrospective analysis of molecular profiles in patients with biliary tract cancers to assess the efficacy of immune checkpoint inhibitors according to KRAS mutation.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: